Axsome Therapeutics (NASDAQ:AXSM) Price Target Increased to $127.00 by Analysts at Citigroup

Axsome Therapeutics (NASDAQ:AXSM – Free Report) had its price target hoisted by Citigroup from $125.00 to $127.00 in a research report report published on Tuesday morning, Benzinga reports. Citigroup currently has a buy rating on the stock. Other equities research analysts also recently issued reports about the company. Robert W. Baird assumed coverage on Axsome […]

Leave a Reply

Your email address will not be published.

Previous post Bitfarms (NASDAQ:BITF) Given “Buy” Rating at HC Wainwright
Next post Bitcoin Depot (NASDAQ:BTM) Price Target Lowered to $4.00 at HC Wainwright